ACTR6

Across TCGA pan-cancer cohorts, ACTR6 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of ACTR6’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ACTR6 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ACTR6 is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

LIHC, HNSC, and BRCA are the cancer types where ACTR6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACTR6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	All	+0.818	<.001	9	view →
HNSC	All	III,IV	+0.553	<.001	8	view →
BRCA	All	III,IV	+0.425	.004	6	view →
BLCA	All	All	+0.419	.003	6	view →
KICH	Female	All	−0.865	<.001	5	view →
LUSC	All	All	+0.497	<.001	5	view →
THCA	All	All	−0.220	.003	4	view →
CHOL	All	All	+1.225	<.001	3	view →
ESCA	All	All	+0.481	.002	2	view →
LUAD	Male	All	+0.275	.039	2	view →
LUAD	Female	II,III,IV	−0.416	.018	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 10 lineages.

ACTR6–LIHC

Open the LIHC breakdown →